Physiomics Reports Interim Financial Results and Strategic Growth Initiatives

Physiomics ( (GB:PYC) ) has issued an announcement.

Physiomics plc reported interim financial results for the six-month period ending December 31, 2024, showing a slight decrease in revenue and an increase in operating loss compared to the previous year. Despite these financial challenges, the company has established a strong pipeline with new contracts and expanded its service offerings, including the launch of a Biostatistics service line and the development of Personalized Medicine Dosing Software. The company completed a successful fundraising effort, enhancing its cash position, and is on track to meet market expectations for the year, driven by a robust second half and strategic growth initiatives.

More about Physiomics

Physiomics plc is a leading company in the field of mathematical modelling, data science, and biostatistics, primarily supporting the development of new therapeutics and personalized medicine solutions. The company combines expertise in Modelling & Simulation, Biostatistics, Data Science, and Bioinformatics to assist biotech and pharma companies in optimizing their drug development processes.

YTD Price Performance: -38.00%

Average Trading Volume: 4,954,372

Technical Sentiment Consensus Rating: Buy

Current Market Cap: £1.41M

Find detailed analytics on PYC stock on TipRanks’ Stock Analysis page.